Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Atreca raises $125mm through Series C round

Executive Summary

Cancer immunotherapies developer Atreca Inc. raised $125mm through an oversubscribed Series C round from investors including returning backers Wellington Management and Cormorant Asset Management; a US-based health care-focused fund, which has invested in Atreca before and led the current round; and new investors Aisling Capital, Boxer Capital (Tavistock), EcoR1 Capital, Redmile Group, Samsara BioCapital, and funds managed by Tekla Capital Management. Proceeds will help the company advance its lead candidate ATR101 into clinical trials for solid tumors including breast, lung, and colon cancers.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies